drugset
drugset / Trial / NCT03096223

A Phase 1 Study of KHK4083 in Subjects With Atopic Dermatitis

NCT03096223 ↗

Phase 1 Completed 26 enrolled Kyowa Kirin, Inc.
NaSingle-groupOpen-labelTreatment

Summary

The objective of this study is to evaluate the safety and tolerability of multiple intravenous (IV) infusions of KHK4083 in subjects with moderate or severe atopic dermatitis.

Timeline

Start
2017-04-10
Primary completion
2018-02-07
Completion
2018-02-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Rocatinlimab Monoclonal antibody — Intravenous

Indications

atopic eczema